CClinicalTrials.gg
CompletedNCT01273233Updated Mar 15, 2013

Safety of an Inactivated Enterovirus Type 71 Vaccine in Healthy Adults

A Phase 1 interventional study of Inactivated Enterovirus Type 71 Vaccine and Placebo in Infection; Viral, Enterovirus, sponsored by Sinovac Biotech Co., Ltd. Completed at 1 site in China. Open to participants aged 18 Years to 49 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2013-03-15.

Sponsored by Sinovac Biotech Co., Ltd · Phase 1, Interventional, and Prevention

Phase
Phase 1
Study type
Interventional
Enrollment
36
Allocation
Randomized
Ages
18 Years to 49 Years
Sex
All
01

Study summary

A blind, randomized and placebo-controlled clinical trial with Inactivated Enterovirus Type 71 Vaccines in healthy adults

Read the detailed description

A total of 36 eligible subjects aged from 18 to 49 years will be enrolled in the study, they will be randomized to receive two different dosage of vaccine candidate or placebo to evaluate the safety of this vaccine in adults

02

Conditions studied

  • Infection; Viral, Enterovirus
03

In context

Enterovirus Infections

47 studies on the registry are indexed under Enterovirus Infections; 5 are open to participants now.

This study's enrollment of 36 is below the median of 150 across 31 interventional studies indexed under Enterovirus Infections.

Browse Enterovirus Infections studies →

Lead sponsor

Sinovac Biotech Co., Ltd is the lead sponsor of 89 studies on the registry; 18 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 49 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Inclusion criteria

  1. Healthy males and females, aged from 18 to 49 years old. Health is determined by medical history, physical examination, laboratory examination and clinical judgment of the investigator
  2. Provided legal identification for the sake of recruitment.
  3. Subjects are able to understand and sign informed consents.

Exclusion criteria

Exclusion Criteria:

  1. Histroy of Hand-foot-mouth Disease
  2. Women of lactation, pregnancy or about to be pregnant in 60 days
  3. Subject that has allergic history of vaccine, or allergic to any ingredient of vaccine
  4. Serious adverse reactions to vaccines such as anaphylaxis, hives, respiratory difficulty, angioedema, or abdominal pain
  5. Congenital malformations or developmental disorders, genetic defects, or severe malnutrition
  6. Epilepsy, seizures or convulsions history, or family history of mental illness
  7. Autoimmune disease or immunodeficiency, or parents, brothers and sisters have autoimmune diseases or immunodeficiency
  8. History of asthma, angioedema, diabetes or malignancy
  9. History of thyroidectomy or thyroid disease that required medication within the past 12 months
  10. Bleeding disorder diagnosed by a doctor (e.g. factor deficiency, coagulopathy, or platelet disorder requiring special precautions) or significant bruising or bleeding difficulties with IM injections or blood draws
  11. Asplenia, functional asplenia or any condition resulting in the absence or removal the spleen
  12. Acute illness or acute exacerbation of chronic disease within the past 7 days
  13. Any history of immunosuppressive medications or cytotoxic medications or inhaled corticosteroids within the past six months (with the exception of corticosteroid nasal spray for allergic rhinitis or topical corticosteroids for an acute uncomplicated dermatitis)
  14. History of any blood products within 3 months
  15. Administration of any live attenuated vaccine within 28 days
  16. Administration of subunit or inactivated vaccines ,e.g., pneumococcal vaccine, or allergy treatment within 14 days
  17. Axillary temperature > 37.0 centigrade before vaccination
  18. Abnormal laboratory parameters before vaccination
  19. Any medical, psychiatric, social condition, occupational reason or other responsibility that, in the judgment of the investigator, is a contraindication to protocol participation or impairs a volunteer's ability to give informed consent
05

Study design

Phase
Phase 1
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
36 participants (actual)

Study arms

  • Experimental
    Group 1: 200U EV71 vaccine

    12 adults received 3 doses of 200U EV71 vaccine 14 days apart

    Biological: Inactivated Enterovirus Type 71 Vaccine

  • Experimental
    Group 2: 400U EV71 vaccine

    12 adults received 3 doses of 400U EV71 vaccine 14 days apart

    Biological: Inactivated Enterovirus Type 71 Vaccine

  • Placebo comparator
    Group 1: Placebo

    6 adults received 3 doses of placebo 14 days apart

    Other: Placebo

  • Placebo comparator
    Group 2: Placebo

    6 adults received 3 doses of placebo 14 days apart

    Other: Placebo

Interventions

  • BiologicalInactivated Enterovirus Type 71 Vaccine

    A Sinovac EV71 vaccine contains inactivated EV71 virus, aluminum hydroxide, sodium chloride, disodium hydrogen phosphate, sodium dihydrogen phosphate and injection water. The EV71 vaccine is supplied in one mono-dose vial containing 0.5 mL of viral suspension with EV71 virus antigen of 200U and 400U (Elisa unit)

    Also known as: EV71 Vaccine

  • OtherPlacebo

    Placebo is suspension with a little ivory precipitation, composition of which is aluminum hydroxide diluents.

    Also known as: EV71 Vaccine

06

What researchers measure

Primary outcomes

  1. To evaluate the safety and tolerability of the inactivated Enterovirus Type 71 Vaccine in adults by different doses

    Time frame: 3 months

07

Study locations

1 site
  • GuangXi Center for Diseases Control and Prevention
    Nanning, Guangxi, China
08

References and documents

Publications

  • Li YP, Liang ZL, Gao Q, Huang LR, Mao QY, Wen SQ, Liu Y, Yin WD, Li RC, Wang JZ. Safety and immunogenicity of a novel human Enterovirus 71 (EV71) vaccine: a randomized, placebo-controlled, double-blind, Phase I clinical trial. Vaccine. 2012 May 9;30(22):3295-303. doi: 10.1016/j.vaccine.2012.03.010. Epub 2012 Mar 15. PubMed 22426327 ↗
09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Mar 15, 2013, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01273233
Lead sponsor
Sinovac Biotech Co., Ltd
Responsible party
Sponsor
First posted
Jan 10, 2011
Start date
Dec 2010
Primary completion
Feb 2011
Completion
Feb 2011
Last update
Mar 15, 2013

Study contacts

Yan-ping Li, MD
principal investigator · Guangxi Centers for Disease Control and Prevention

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2013. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion